Barbara Grant

6.0k citations

32 papers · 2.4k indexed · 1 hit paper · h-index 17

Impact in

Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 20
- Chronic Lymphocytic Leukemia Research 14
- Glioma Diagnosis and Treatment 5
Pathology and Forensic Medicine 16
- Lymphoma Diagnosis and Treatment 16

Co-authors: Richard R. Furman Ahmed Hamdy Jeff P. Sharman Nathan Fowler Joseph J. Buggy Thomas E. Boyd Kathryn S. Kolibaba Ranjana H. Advani
Journals: Journal of Clinical Oncology (10 papers)Blood (9 papers)Cancer (2 papers)Biomaterials (1 paper)Acta Haematologica (1 paper)
Partner nations: United States Switzerland Israel

In The Last Decade

Barbara Grant

30 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies 2012 · 848 citations

Peers

Countries citing papers authored by Barbara Grant

Since Specialization

Citations

This map shows the geographic impact of Barbara Grant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Grant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Grant more than expected).

Fields of papers citing papers by Barbara Grant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Grant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Grant. The network helps show where Barbara Grant may publish in the future.

Co-authors

The 25 scholars most cited alongside Barbara Grant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Barbara Grant Line = papers co-authored together Barbara Grant links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma Blood Advances ·Sarah C. Rutherford, Jun Yin, Levi Pederson, Kristie A. Blum, Peter Martin, Sin‐Ho Jung, Barbara Grant, Cara A. Rosenbaum, Bruce D. Cheson, Nancy L. Bartlett, Sumithra J. Mandrekar, John P. Leonard	2024	2
2	Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant Acta Haematologica ·Jon Arnason, Katarina Luptakova, Jacalyn Rosenblatt, Dimitrios Tzachanis, Р. С. Мартынов, Jeffrey I. Zwicker, James D. Levine, Michelle Kim, Jefferson Parker, Barbara Grant, Robin Joyce	2015	9
3	Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome Journal of Clinical Oncology ·Patrick G. Morris, Denise D. Correa, Joachim Yahalom, Jeffrey J. Raizer, David Schiff, Barbara Grant, Sean Grimm, Rose Lai, Anne S. Reiner, K. Panageas, Sasan Karimi, Richard Curry, Gaurav Shah, Lauren E. Abrey, Lisa M. DeAngelis, Antonio Omuro	2013	316
4	Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology ·James L. Rubenstein, Eric D. Hsi, Jeffrey L. Johnson, Sin‐Ho Jung, Megan O. Nakashima, Barbara Grant, Bruce D. Cheson, Lawrence D. Kaplan	2013	320
5	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 Cancer ·Barbara Grant, Sin‐Ho Jung, Jeffrey L. Johnson, Lale Kostakoğlu, Eric D. Hsi, John C. Byrd, Jeffrey A. Jones, John P. Leonard, Sabrina Martín, Bruce D. Cheson	2013	42
6	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Journal of Clinical Oncology ·Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Sonali M. Smith, Thomas E. Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Sara Rodríguez, Betty Chang, Juthamas Sukbuntherng, Raquel Izumi, Ahmed Hamdy, Eric Hedrick, Nathan Fowler Hit paper breakdown →	2012	848
7	The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. Journal of Clinical Oncology ·John C. Byrd, Richard R. Furman, Steven Coutré, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Ian W. Flinn, Barbara Grant, Nyla A. Heerema, Amy J. Johnson, Jamal Ahmed Hama Kareem, Danelle F. James, Eric Hedrick, Susan O’Brien	2012	23
8	The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study Blood ·John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Barbara Grant, Jeffrey A. Jones, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Елена Александровна Леонова, Fong Clow, Lori Kunkel, Danelle F. James, Susan O’Brien	2012	44
9	Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. Journal of Clinical Oncology ·John C. Byrd, Omid Mojarad, Jan A. Burger, Steven Coutré, Jeffrey P. Sharman, Richard R. Furman, Ian W. Flinn, Barbara Grant, Donald Richards, Li Jun Hei, NA Heerema, 李清博, Raquel Izumi, Ahmed Hamdy, Susan O’Brien	2011	25
10	The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study Blood ·Susan O’Brien, Jan A. Burger, Kristie A. Blum, Richard R. Furman, Steven Coutré, Jeff P. Sharman, Ian W. Flinn, Barbara Grant, Nyla A. Heerema, Amy J. Johnson, Jamal Ahmed Hama Kareem, Eric Holmgren, Eric Hedrick, John C. Byrd	2011	45
11	The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study Blood ·Nathan Fowler, S. J. Zhu, Sonali M. Smith, Thomas E. Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Joseph J. Buggy, David Loury, Ahmed Hamdy, Ranjana H. Advani	2010	36
12	The induction of cell alignment by covalently immobilized gradients of the 6th Ig-like domain of cell adhesion molecule L1 in 3D-fibrin matrices Biomaterials ·Tessa Lühmann, B. G. Krishnappan, Barbara Grant, Heike Hall	2009	22
13	A multicentre phase II clinical experience with the novel aza‐epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non‐Hodgkin lymphoma and mantle cell lymphoma British Journal of Haematology ·Owen A. O’Connor, Carol S. Portlock, Craig H. Moskowitz, David J. Straus, Paul A. Hamlin, Michael D. Stubblefield, Francisco Quijano, A. Dimitrios Colevas, Barbara Grant, Andrew D. Zelenetz	2008	15
14	Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma Journal of Clinical Oncology ·Gaurav Shah, Joachim Yahalom, Denise D. Correa, Rose Lai, Jeffrey J. Raizer, David Schiff, Renato V. LaRocca, Barbara Grant, Lisa M. DeAngelis, Lauren E. Abrey	2007	281
15	90Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma. Blood ·Pitriyani Nurul Pajar, Javad Baradaran, Pamela Ely, Barbara Grant, J. Anthony Parker, Robin Joyce	2006	0
16	Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487) Cancer ·Arthur I. Radin, Haesook T. Kim, Barbara Grant, John M. Bennett, John M. Kirkwood, James A. Stewart, Richard G. Hahn, Janice P. Dutcher, Peter H. Wiernik, Martin M. Oken	2003	36
17	HPRT mutations in vivo in human CD 34+ hematopoietic stem cells Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Barbara Grant, Lucy Trombley, Timothy C. Hunter, 博也浜, John P. O’Neill, Heena Patel	1999	5
18	Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. PubMed ·James A. Stewart, Jerome L. Belinson, Ann L. Moore, Bingul, Barbara Grant, Larry D. Haugh, John D. Roberts, Richard J. Albertini, Richard F. Branda	1990	54
19	Proliferation and Maturation of Human Megakaryocytes in Vitro Annals of the New York Academy of Sciences ·Barbara Grant, Lawrence A. Solberg, Larry B. Wimmer, Kenneth G. Mann	1987	2
20	Immune cell populations in cutaneous delayed-type hypersensitivity. The Journal of Experimental Medicine ·Jeffrey L. Platt, Barbara Grant, Allison A. Eddy, Gordon A Ferns	1983	157

About Barbara Grant

Barbara Grant is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Neurology and Radiology, Nuclear Medicine and Imaging, having authored 32 papers that have together received 2.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (14 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), CNS Lymphoma Diagnosis and Treatment (6 papers), Glioma Diagnosis and Treatment (5 papers), Immune Cell Function and Interaction (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Genetics (1.6k citations), Pathology and Forensic Medicine (1.6k citations), Neurology (901 citations), Hematology (337 citations) and Immunology (456 citations). Barbara Grant has collaborated with scholars based in United States, Switzerland and Israel. Frequent co-authors include Richard R. Furman, Ahmed Hamdy, Jeff P. Sharman, Nathan Fowler, Joseph J. Buggy, Thomas E. Boyd, Kathryn S. Kolibaba, Ranjana H. Advani, Eric Hedrick and Sonali M. Smith. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer, Biomaterials and Acta Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact